medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-19-12-16medsovet-2740Research ArticleИММУНОТЕРАПИЯ В ОНКОЛОГИИImmunotherapy in oncologyПерспективы иммунотерапии рака молочной железыFuture prospects for breast cancer immunotherapyСемиглазовВ. Ф.SemiglazovV. F.

д.м.н., профессор, врач-онколог, чл.-корр. РАН, заслуженный деятель науки РФ, председатель СанктПетербургского научного общества онкологов, президент Российского общества онкомаммологов (РООМ), заведующий научного отдела опухолей репродуктивной системы

ЦелуйкоА. И.TseluikoA. I.

врач-онколог, хирург, врач клинико-диагностического отделения

ДонскихР. В.DonskikhR. V.

к.м.н., врач-онколог, заместитель главного врача по медицинской части

КриворотькоП. В.KrivorotkoP. V.

д.м.н., врач-онколог, хирург, заведующий отделением опухолей молочной железы, ведущий научный сотрудник

ДашянГ. А.DashyanG. A.

д.м.н., врач-онколог, хирург, ведущий научный сотрудник отделения опухолей молочной железы

СемиглазовВ. В.SemiglazovV. V.КомяховА. В.KomyakhovA. V.

к.м.н., врач-онколог, хирург, научный сотрудник отделения опухолей молочной железы

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России, Санкт-ПетербургРоссияPetrov National Medical Cancer Research Centre, the Ministry of Russia, St.Petersburg, RussiaRussian Federation2018111120180191216Copyright © Семиглазов В.Ф., Целуйко А.И., Донских Р.В., Криворотько П.В., Дашян Г.А., Семиглазов В.В., Комяхов А.В., 20182018Семиглазов В.Ф., Целуйко А.И., Донских Р.В., Криворотько П.В., Дашян Г.А., Семиглазов В.В., Комяхов А.В.Semiglazov V.F., Tseluiko A.I., Donskikh R.V., Krivorotko P.V., Dashyan G.A., Semiglazov V.V., Komyakhov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2740

Иммунотерапия уже стала важным компонентом стандартного лечения больных распространенным раком. Большинство методов лечения включают в себя моноклональные антитела (mAbs), блокирующие иммунные контрольные точки (chekpoint), в частности рецептор запрограммированной гибели клеток 1 (PD-1) и его лиганд 1 (PD-L1), или направленные на Т-лимфоцит-ассоциированный белок 4 (CTLA-4). Будущее иммуноонкологии будет состоять в том, чтобы определить, могут ли данные агенты быть более эффективными при назначении их в послеоперационном адъювантном или в неоадъювантном режиме до хирургического лечения. Вакцинотерапия показала многообещающие результаты, и особенно данная терапия привлекательна ввиду отсутствия выраженной токсичности.

 

Immunotherapy has already become an important component of the standard treatment of patients with advanced cancer. Most treatment methods include monoclonal antibodies (mAbs) that block immune checkpoints, in particular, the programmed cell death 1 (PD-1) receptor and its ligand 1 (PD-L1) or are directed against T-lymphocyte-associated protein 4 (CTLA-4). The future prospects for immuno-oncology will be to determine whether these agents can be more effective if administered in a postoperative adjuvant or in a neoadjuvant regimen prior to surgical treatment. Vaccine therapy has shown promising results, and this therapy is especially attractive due to absence of pronounced toxicity.

рак молочной железыиммуноонкологияиммунотерапияbreast cancerimmuno-oncologyimmunotherapyReferencesDenkert C, Loibl S, Noske A, et al. Tumorassociated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol, 2010, 28: 105-113.Denkert C, Loibl S, Noske A, et al. Tumorassociated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol, 2010, 28: 105-113.Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol, 2015, 33: 983–91.Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol, 2015, 33: 983–91.Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med, 2016, 13: e1002194.Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med, 2016, 13: e1002194.Berke G, The binding and cellular aspects. Ann Rev Immunol, 1994, 12: 735-773.Berke G, The binding and cellular aspects. Ann Rev Immunol, 1994, 12: 735-773.Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol, 2011, 8: 151-160.Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol, 2011, 8: 151-160.Zitvogel L, Galluzzi L, Kepp O, SmythMJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol, 2015, 15(7): 405-414.Zitvogel L, Galluzzi L, Kepp O, SmythMJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol, 2015, 15(7): 405-414.Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res, 2008, 68: 889-892.Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res, 2008, 68: 889-892.Semiglazov VF. Dependence of clinical course in breast cancer on pathology. Radiobiol Radiother, 1974, 3: 361-364.Semiglazov VF. Dependence of clinical course in breast cancer on pathology. Radiobiol Radiother, 1974, 3: 361-364.Семиглазов В.Ф., Криворотько П.В., Семиглазов В.В., Дашян Г.А., Палтуев Р.М. Рекомендации для врачей по ведению пациентов с раком молочной железы. М.: Ремедиум, 2017. 240 с.Semiglazov VF, Krivorotko PV, Semiglazov VV, Dashyan GA, Paltuev RM. Guidelines for physicians concerning management of patients with breast cancer. M.: Remedium, 2017. 240 p.Хаитов Р.М., Кадаидзе З.Г. Иммунитет и рак. М.: ГЭОТАР-Медиа, 2018, 251 с.Khaitov RM, Kadaidze ZG. Immunity and cancer. M.: GEOTAR-Media, 2018, 251 p.Петров Р.В., Хаитов Р.М. Иммунология и вакцины нового поколения. М.: ГЭОТАРМедиа, 2011, 608 с.Petrov RV, Khaitov RM. Immunology and new generation vaccines. M.: GEOTAR-Media, 2011, 608 p.Семиглазов В.Ф., Семиглазов В.В. Лечение рака молочной железы. Клиникобиологическое обоснование. М.: СИМК, 2017. 227 с.Semiglazov VF, Semiglazov VV. Breast cancer treatment. Clinical and biological study. M.: SIMK, 2017. 227 p.Кадагидзе З.Г., Черткова А.И., Славина Е.Г. Регуляторные Т-клетки и их роль в противоопухолевом иммунном ответе. Вопросы онкологии, 2009, 55(3): 269-277.Kadagidze ZG, Chertkova AI, Slavina EG. Regulatory T-cells and their role in the antitumor immune response. Voprosy Onkologii, 2009, 55 (3): 269-277.Колядина И.В., Поддубная И.В., Van de Velde и соавт. Иммунная гетерогенность рака молочной железы I стадии: биологическое, популяционное и прогностическое значение. Современная онкология, 2015, 17(1): 30-38.Kolyadina IV, Poddubnaya IV, Van de Velde, et al. Immune heterogeneity of stage I breast cancer: biological, population and prognostic value. Sovremennaya Onkologiya, 2015, 17 (1): 30-38.Emens L, Adams S, Loi S. et al. A phase III randomized trial of atezolizumab in combination with nab. paclitaxel as first line therapy for patients with metastatic triple – negative breast cancer (mTNBC). San-Antonio Breast Cancer Simposium. 2015. OT1-01-06.Emens L, Adams S, Loi S. et al. A phase III randomized trial of atezolizumab in combination with nab. paclitaxel as first line therapy for patients with metastatic triple – negative breast cancer (mTNBC). San-Antonio Breast Cancer Simposium. 2015. OT1-01-06.Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Presented at San Antonio Breast Cancer Symposium. December 9-13, 2014. San Antonio, TX.Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Presented at San Antonio Breast Cancer Symposium. December 9-13, 2014. San Antonio, TX.Adams S, Diamond JR, Hamilton EP et al. Phase IB trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol, 2016, 34(Suppl. 15): 1009-1009.Adams S, Diamond JR, Hamilton EP et al. Phase IB trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol, 2016, 34(Suppl. 15): 1009-1009.Perdoza-Gonzalez A, Xu K, Wu TC, et al. Thymic stromal lemphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med, 2011, 208: 479-490.Perdoza-Gonzalez A, Xu K, Wu TC, et al. Thymic stromal lemphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med, 2011, 208: 479-490.Cecil DL, Holt GE, Park KH, et al. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res, 2014, 74: 2710-2718.Cecil DL, Holt GE, Park KH, et al. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res, 2014, 74: 2710-2718.Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med, 2005, 353(25): 2654-2666.Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med, 2005, 353(25): 2654-2666.HwangWT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumorinfiltrating T cells in ovarian cancer: ametaanalysis. Gynecol Oncol, 2012, 124(2): 192-198.HwangWT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumorinfiltrating T cells in ovarian cancer: ametaanalysis. Gynecol Oncol, 2012, 124(2): 192-198.Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with nonsmall-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol, 2008, 26(27): 4410-4417.Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with nonsmall-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol, 2008, 26(27): 4410-4417.Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer, 2012, 12(4): 298-306.Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer, 2012, 12(4): 298-306.Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol, 2007, 19(2): 209-216.Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol, 2007, 19(2): 209-216.Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer, 2006, 94: 259-267Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer, 2006, 94: 259-267

The authors declare that there are no conflicts of interest present.